Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-06-14
1998-12-08
Low, Christopher S. F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4242341, 435 6, 435 691, 4351723, 435325, 4353201, 935 62, 935 56, 935 34, 935 65, A61K 4800
Patent
active
058469460
ABSTRACT:
Plasmid DNA encoding at least one Borrelia genospecies antigen and methods for making and using such a plasmid are disclosed and claimed. The genospecies can be burgdorferi, garinii and/or afzelli. The antigen can be OspA and/or OspB and/or OspC. Compositions containing the plasmid DNA are useful for administration to a host susceptible to Lyme Disease for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens in vitro. And, the inventive plasmid can be prepared by isolating DNA (such as DNA coding for: promoter, leader sequence, antigen, and terminator) and performing a ligation or ligations, such as a three-way ligation. More particularly, administration of DNA encoding Borrelia genospecies antigen, e.g., OspA and/or OspB and/or OspC and compositions therefor for eliciting an immunological response against Borrelia, such as a protective response preventive of Lyme Disease, are disclosed and claimed. Thus, Lyme Disease vaccines or immunological compositions, and methods of making and using them, are disclosed and claimed.
REFERENCES:
patent: 5122458 (1992-06-01), Post et al.
patent: 5558993 (1996-09-01), Champion et al.
patent: 5571718 (1996-11-01), Dunn et al.
patent: 5688512 (1997-11-01), Bergstrom et al.
Robinson et al., Seminars in Immunology, vol. 9, pp. 271-283, 1997.
Barbour, Lyme Disease, the cause, the cure, the controversy. The Johns Hopkins University Press, 1997, pp. 240 and 241.
Probert et al. Infection and Immunity. May 1994. vol. 62(5):1920-6, May 9, 1998.
Bockenstedt et al. J. Innumology. 1993, 151(2):900-906, May 9, 1998.
Schaible et al. Vaccine. 1993, vol. 11(10):1049-54, May 9, 1998.
Montgomery et al. J. of Exp. Med. 1996, 183, 1:261-69.
Fikrig et al. Infection and Immunity. Feb. 1992. vol. 60, No. 2:657-661.
Rappuoli et al. Vaccine. 1996, vol. 14, No. 7:691-716.
Eisenbraun et al. DNA and Cell Biology. 1996, vol. 2, No. 3:168-175.
Mendoza-Vega et al. Applied Microb. Biotech. 1996 Jan. vol. 44(5):624-8.
Katsumi et al. Hum. Gene. Ther. 1994, 5:1335-1339.
Pardoll et al. Immunity. 1995, 3(2):165-9.
Robert Whalen. Emerging Infectious Diseases. 1996, vol. 2, No. 3:168-175.
Barbour Alan G.
Carner Kristin R.
Huebner Robert C.
Liang Xiaowu
Luke Catherine J.
Frommer William S.
Kowalski Thomas J.
Low Christopher S. F.
Nguyen Dave Trong
Pasteur Merieux Serums et Vaccins
LandOfFree
Compositions and methods for administering Borrelia DNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for administering Borrelia DNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for administering Borrelia DNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177349